Jeff Ratliff

Dr. Jeff Ratliff, a medical expert in neurology, discusses the groundbreaking FDA approval of Crexant, a new extended-release medication for Parkinson's disease. He delves into its potential to improve motor function and shares insights from the RISE PD trial. The conversation also covers the formulation of the drug and its implications for clinical practice, offering hope for those affected by this challenging condition.

Dr. Jeff Ratliff, a clinical expert in dopaminergic imaging, joins Dr. Eduardo De Pablo-Fernández, a specialist in clinical interpretations, to discuss critical insights into the limitations of DAT imaging in diagnosing Parkinsonism. They caution against over-reliance on imaging, highlighting potential pitfalls in cases like corticobasal syndrome and progressive supranuclear palsy. The conversation emphasizes the need for careful consideration in differential diagnosis to avoid misleading interpretations.

Join medical professionals Jeff Ratliff and Nanditha Rajamani, along with researcher Andy Horn, as they explore deep brain stimulation (DBS) for Parkinson's disease. They delve into how DBS can improve motor symptoms by targeting specific white matter tracts. The discussion highlights a groundbreaking study that correlates symptom relief with tailored DBS programming, paving the way for more personalized treatments. This insightful conversation sheds light on the future of Parkinson's care!

In this riveting discussion, Dr. Calium, a knowledgeable expert on MCI and dementia risk, joins Dr. Jeff Ratliff, an experienced practitioner in neurodegenerative diseases. They delve into the progression rates of Mild Cognitive Impairment (MCI) toward dementia in patients with Lewy Bodies and Alzheimer's Disease. Alarming statistics emerge, highlighting the critical need for further research and understanding of these conditions. Listeners gain valuable insights into patient outcomes at three and five-year benchmarks.

Dr. Jeff Ratliff, a leading expert in neurology, dives into groundbreaking research on deep brain stimulation for Parkinson's disease. He unpacks the advancements in adaptive deep brain stimulation, which tailors treatment using real-time neurophysiological data. This innovative approach promises improved motor symptom management, offering hope for more personalized therapy. Ratliff's insights reveal the potential of adaptive DBS to outperform conventional stimulation methods, paving the way for a new era in Parkinson's disease treatment.

Dr. Calum Alexander Hamilton, an expert on managing mild cognitive impairment (MCI), joins Dr. Jeff Ratliff, who specializes in outcomes for Lewy body pathology. They delve into the critical importance of monitoring patients with MCI, particularly those at risk of progressing to dementia. The conversation highlights alarming rates of dementia development among these individuals, comparing the timelines for Lewy bodies versus Alzheimer’s disease. They also stress the vital role of brain tissue donation in enhancing diagnostic accuracy and understanding of dementia subtypes.

Dr. Jeff Ratliff, a dedicated researcher, joins Dr. Daniel Weintraub, a noted expert on dementia in Parkinson's disease, to discuss the evolving understanding of long-term dementia risk. They reveal that up to 80% of Parkinson's patients may develop dementia over 15 to 20 years, challenging earlier beliefs about onset timing. Exploration of biomarkers offers new insights into cognitive decline. The conversation also emphasizes holistic approaches, advocating for regular cognitive screenings and considering non-motor symptoms in patient care.

Dr. Jeff Ratliff, a specialist in dopaminergic imaging techniques, teams up with Dr. Eduardo De Pablo-Fernández, an expert in Parkinsonian disorder diagnostics. They delve into the vital role of dopamine transporter imaging in diagnosing Parkinsonism, highlighting its impressive negative predictive value. The conversation also touches on the limitations of this imaging method, providing a balanced view of its efficacy in clinical settings. Listeners gain key insights into how imaging impacts the diagnosis and management of these complex disorders.

Dr. Jeff Ratliff, a specialist in DAT imaging, joins Dr. Eduardo De Pablo-Fernández, an expert on Parkinsonian disorders, to discuss the critical role of dopamine transporter imaging in diagnosis. They explore how DAT imaging can effectively differentiate between Parkinson's disease and multiple system atrophy, while also addressing its limitations in tau-related conditions. Key insights include the influence of alpha-synuclein on neurodegenerative disorders and the challenges of interpreting imaging results, particularly for progressive supranuclear palsy.

Dr. Jeff Ratliff, a medical professional specializing in movement disorders, dives deep into emergent rigidity and movement difficulties. He emphasizes the importance of thorough patient assessment and reviews critical medication histories. The discussion highlights serious complications like neuroleptic malignant syndrome and serotonin syndrome, advocating for both supportive care and necessary medication adjustments. Dr. Ratliff’s insights provide essential strategies for managing these complex emergencies effectively.